Through the GEMO study, blood DNA from BRCA1/2 mutation carriers is available to perform genetic epidemiological projects aiming at identifying and characterizing genetic factors modifying breast and ovarian cancer risk. Here, BRCA1 is linked to ovarian carcinoma.